Increased bioactive TNF in human systemic lupus erythematosus:: associations with cell death

被引:87
作者
Aringer, M
Feierl, E
Steiner, G
Stummvoll, GH
Höfler, E
Steiner, CW
Radda, I
Smolen, JS
Graninger, WB
机构
[1] Univ Vienna, Dept Rheumatol, AKH, A-1090 Vienna, Austria
[2] Lainz Hosp, Dept Internal Med 2, Vienna, Austria
关键词
SLE; TNF; TNF-receptor; apoptosis; CD95;
D O I
10.1191/0961203302lu160oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In systemic lupus erythematosus (SLE) serum TNF is increased and correlates with its soluble receptors and with disease activity. We therefore investigated (i) whether the TNF in SLE serum is bioactive, (ii) whether SLE cells react to TNF and (iii) whether there are associations with cell death, which is regarded as pathogenic in SLE. Sera from active SLE patients induced an increase in fibroblast CD54, which was abolished by blocking antibodies against TNF, suggesting TNF bioactivity. SLE lymphocytes had a similar surface expression of TNF-RI as healthy lymphocytes, their expression of TNF-RII was slightly increased. Recombinant TNF induced cell death in PBMC of SLE patients, suggesting functional receptors. Serum levels of sTNF-RII (as a surrogate marker for TNF activity) correlated with sTNF-RI and disease activity, as expected, and also correlated with the percentage of dying lymphocytes and with lymphocytic CD95. SLE sera contain increased amounts of biologically active TNF. Peripheral blood lymphocytes of SLE patients express functional TNF receptors. Finally, associations with cell death and CD95 receptors suggest that TNF may be pathogenic in SLE.
引用
收藏
页码:102 / 108
页数:7
相关论文
共 52 条
  • [1] CORRELATION BETWEEN SERUM LEVELS OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR AND DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    ADERKA, D
    WYSENBEEK, A
    ENGELMANN, H
    COPE, AP
    BRENNAN, F
    MOLAD, Y
    HORNIK, V
    LEVO, Y
    MAINI, RN
    FELDMANN, M
    WALLACH, D
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (08): : 1111 - 1120
  • [2] Apoptosis in systemic lupus erythematosus - Clinical implications
    Andrade, F
    Casciola-Rosen, L
    Rosen, A
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) : 215 - +
  • [3] Aringer M, 2001, ARTHRITIS RHEUM, V44, P1721, DOI 10.1002/1529-0131(200107)44:7<1721::AID-ART302>3.0.CO
  • [4] 2-J
  • [5] Serum interleukin-15 is elevated in systemic lupus erythematosus
    Aringer, M
    Stummvoll, GH
    Steiner, G
    Köller, M
    Steiner, CW
    Höfler, E
    Hiesberger, H
    Smolen, JS
    Graninger, WB
    [J]. RHEUMATOLOGY, 2001, 40 (08) : 876 - 881
  • [6] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
    Bathon, JM
    Martin, RW
    Fleischmann, RM
    Tesser, JR
    Schiff, MH
    Keystone, EC
    Genovese, MC
    Wasko, MC
    Moreland, LW
    Weaver, AL
    Markenson, J
    Finck, BK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1586 - 1593
  • [7] BENCIVELLI W, 1992, CLIN EXP RHEUMATOL, V10, P549
  • [8] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
    BOMBARDIER, C
    GLADMAN, DD
    UROWITZ, MB
    CARON, D
    CHANG, CH
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (06): : 630 - 640
  • [9] BOSWELL JM, 1988, J IMMUNOL, V141, P3050
  • [10] BRENNAN DC, 1989, J IMMUNOL, V143, P3470